• Satellos Bioscience published an interim six-month update from its Phase 2 TRAILHEAD study of SAT-3247 in adults with Duchenne muscular dystrophy.
• Study readout covered four adults aged 21-28; mean drug exposure 186 days; 100% compliance.
• No serious treatment-emergent adverse events; no withdrawals or discontinuations tied to adverse events.
• MRI biceps fat fraction fell 3.7% on average by month 5; declines reported in all four participants.
• Wearable-measured total effort rose about 34% by month 6; upper-extremity strength measures held stable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.